BriaCell Therapeutics Corp. (BCTX)

2.2200 +0.1100 (+5.21%) 市場開市。 截至 03:32PM EDT。

BriaCell Therapeutics Corp.

Bellevue Centre
Suite 300 235 -15th Street
West Vancouver, BC V7T 2X1
Canada
604 921 1810
https://briacell.com

版塊: Healthcare
行業: Biotechnology
全職員工: 16

高階主管

名稱	頭銜	支付	行使價	出生年份
Dr. William V. Williams M.D.	CEO, President & Director	785.3k	無	1955
Mr. Gadi Levin B.Com., C.A., CPA, M.B.A.	CFO & Corporate Secretary	304.46k	無	1973
Dr. Miguel A. Lopez-Lago Ph.D.	Chief Scientific Officer	298.9k	無	1969
Dr. Giuseppe Del Priore M.D., M.P.H., MPH	Chief Medical Officer	492.5k	無	1962
Dr. Charles Louis Wiseman FACP, M.D.	Founder, Principal Research Advisor & Member of Scientific Advisory Board	241.14k	無	1946

截止 2023年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 USD。

描述

BriaCell Therapeutics Corp. operates as a Phase 3 biotechnology company transforming cancer care with its novel cellular immunotherapies. It is conducting a pivotal Phase 3 clinical trial in advanced breast cancer with its Bria-IMT in combination with an immune check point inhibitor. It is also developing personalized off-the-shelf treatments for breast cancer, prostate cancer, and other cancers. The company has a collaboration with Incyte Corporation to evaluate combination of the Bria-IMT. BriaCell Therapeutics Corp. is based in West Vancouver, Canada.

公司管治

截至 無 止，BriaCell Therapeutics Corp. 的 ISS 管治質素評分為 無。 Pillar 分數正在審核中：無；董事會：無；股東權利：無；現金賠償：無。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。